InvestorsHub Logo
Followers 15
Posts 1647
Boards Moderated 0
Alias Born 05/15/2015

Re: None

Monday, 05/23/2016 2:03:05 PM

Monday, May 23, 2016 2:03:05 PM

Post# of 34575
Astra/Zeneca ASCO abstract to hi-light immune oncology.




"AstraZeneca PLC (NYSE: AZN) will present 73 abstracts at ASCO, with 19 related to olaparib and new potential medicines targeting DNA damage response in multiple tumor types. Most of these abstracts accentuate the continued progress of the company’s oncology pipeline, as well as new data behind this momentum in AstraZeneca’s immune-oncology programs, small molecule developments and leukemia treatments".


Link
http://247wallst.com/healthcare-business/2016/05/19/8-stocks-on-the-move-after-asco-cancer-abstracts/


Note: Quite interesting to see if little partner TapImmune, TPIV, gets some action via these highly anticipated abstracts.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News